Determination of the in vivo selectivity of a new κ-opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1668-1674

  Kim, Su Jin ^a,b   Zheng, Ming Qiang ^a,b   Nabulsi, Nabeel ^a   Labaree, David ^a   Ropchan, Jim ^a   Najafzadeh, Soheila ^a   Carson, Richard E ^a,b,c   Huang, Yiyun ^a,b   Morris, Evan D ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c Yale University   (United States)

Author keywords

In vivo; K opioid receptor; PET; Selectivity

Indexed keywords

CARBON CARFEBTANIL C 11; CARBON LY 2795050 C 11; DIAGNOSTIC AGENT; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3 CHLORO 4 (4 ((2 (3 PYRIDYL)PYRROLIDIN 1 YL)METHYL)PHENOXY)BENZAMIDE; 3-CHLORO-4-(4-((2-(3-PYRIDYL)PYRROLIDIN-1-YL)METHYL)PHENOXY)BENZAMIDE; BENZAMIDE DERIVATIVE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHESUS MONKEY; Κ-OPIOID RECEPTOR; ANIMAL; BIOLOGICAL MODEL; BRAIN; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; DRUG ANTAGONISM; IN VIVO; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PET; REPRODUCIBILITY; SCINTISCANNING; SELECTIVITY; SENSITIVITY AND SPECIFICITY; SYNTHESIS; TISSUE DISTRIBUTION;

Κ-OPIOID RECEPTOR; IN VIVO; PET; SELECTIVITY;

ANIMALS; BENZAMIDES; BRAIN; COMPUTER SIMULATION; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MACACA MULATTA; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, OPIOID, KAPPA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84887379646     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118877     Document Type: Article

References (32)

1. Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther. 2007;116:306-321.
2. Mucha RF, Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl). 1985;86:274-280.
3. Yakovleva T, Marinova Z, Kuzmin A, et al. Dysregulation of dynorphins in Alzheimer disease. Neurobiol Aging. 2007;28:1700-1708.
4. Kovacs KM, Szakall I, O'Brien D, et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res. 2005;29:730-738.
5. Marinelli PW, Kiianmaa K, Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci. 2000;66:1915-1927.
6. Fadda P, Tronci S, Colombo G, Fratta W. Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol Clin Exp Res. 1999;23:1296-1305.
7. Winkler A, Spanagel R. Differences in the kappa opioid receptor mRNA content in distinct brain regions of two inbred mice strains. Neuroreport. 1998;9:1459-1464.
8. Edenberg HJ, Wang J, Tian H, et al. A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum Mol Genet. 2008;17:1783-1789.
9. Weerts EM, Wand GS, Kuwabara H, et al. Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res. 2011;35:2162-2173.
10. Weerts EM, Kim YK,Wand GS, et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33:653-665.
11. Ravert HT, Mathews WB, Musachio JL, Scheffel U, Finley P, Dannals RF. [11C]-methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl)-methyl]-1- piperazinecarboxylate ([11C]GR89696): synthesis and in vivo binding to kappa opiate receptors. Nucl Med Biol. 1999;26:737-741.
12. Talbot PS, Narendran R, Butelman ER, et al. 11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. J Nucl Med. 2005;46:484-494.
13. Poisnel G, Oueslati F, Dhilly M, et al. [11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging. Nucl Med Biol. 2008;35:561-569.
14. Tomasi G, Zheng M-Q, Weinzimmer D, et al. Kinetic modeling of the kappa agonist tracer [11C]GR103545 in humans [abstract]. J Nucl Med. 2010;51 (suppl 2):1293.
15. Thomas JB, Atkinson RN, Vinson NA, et al. Identification of (3R)-7-hydroxy-N- ((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl]methyl]-2- methylpropyl)-1,2,3,4-tetrahydro- 3- isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. J Med Chem. 2003;46:3127-3137.
16. Zheng MQ, Nabulsi N, Kim SJ, et al. Synthesis and evaluation of 11CLY2795050 as a k-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med. 2013;54:455-463.
17. Ekelund J, Slifstein M, Narendran R, et al. In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol. 2007;9:117-125.
18. Slifstein M, Hwang DR, Huang Y, et al. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl). 2004;175:274-286.
19. Henriksen G, Willoch F, Talbot PS, Wester HJ. Recent development and potential use of mu- and kappa-opioid receptor ligands in positron emission tomography studies. Drug Dev Res. 2006;67:890-904.
20. NabulsiN,HuangY,Weinzimmer D, et al.High-resolution imagingof brain5-HT1B receptors in the rhesus monkey using [11C]P943. Nucl Med Biol. 2010;37:205-214.
21. Sandiego CM,Weinzimmer D, Carson RE. Optimization of PET-MR registrations for nonhuman primates using mutual information measures: a multi-transform method (MTM). Neuroimage. 2013;64:571-581.
22. Endres CJ, Bencherif B, Hilton J, Madar I, Frost JJ. Quantification of brain muopioid receptors with [11C]carfentanil: reference-tissue methods. Nucl Med Biol. 2003;30:177-186.
23. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
24. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46-50.
25. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22:1271-1281.
26. Sim-Selley LJ, Daunais JB, Porrino LJ, Childers SR. Mu and kappa1 opioidstimulated [35S]guanylyl-59-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain. Neuroscience. 1999;94:651-662.
27. Delay-Goyet P, Zajac JM, Javoy-Agid F, Agid Y, Roques BP. Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects. Brain Res. 1987;414:8-14.
28. Morris ED, Kim SJ, Franco N, et al. Occupancy of naltrexone at kappa opioid receptors may predict efficacy in reducing drinking in alcoholics [abstract]. J Cereb Blood Flow Metab. 2012;32:S91-S92.
29. Ko MC, Butelman ER, Traynor JR, Woods JH. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J Pharmacol Exp Ther. 1998;285:518-526.
30. Searle G, Beaver JD, Comley RA, et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry. 2010;68:392-399.
31. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci. 1988;11:308-314.
32. Pappata S, Dehaene S, Poline JB, et al. In vivo detection of striatal dopamine release during reward: a PET study with [11C]raclopride and a single dynamic scan approach. Neuroimage. 2002;16:1015-1027.